HC Wainwright reaffirmed their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Monday, Stock Target Advisor reports. The firm currently has a $28.00 price objective on the stock.
Separately, ValuEngine downgraded Bio-Path from a hold rating to a sell rating in a report on Friday, October 25th.
Bio-Path stock traded down $0.09 during trading on Monday, hitting $9.88. 497 shares of the company were exchanged, compared to its average volume of 65,245. The business’s 50 day moving average is $10.66 and its 200 day moving average is $12.65. Bio-Path has a 52 week low of $1.61 and a 52 week high of $73.52. The company has a market capitalization of $30.75 million, a P/E ratio of -0.69 and a beta of 3.14. The company has a current ratio of 13.85, a quick ratio of 13.85 and a debt-to-equity ratio of 0.02.
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Featured Article: What is the outlook for the FAANG stocks?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.